Immuneel Therapeutics has raised over ₹100 crore (approximately $10.5 million) through a recent Series B financing round. The fundraising success came through contributions from a number of both new and current investors. Some of the most notable investors included Singularity AMC, Rainmatter by Zerodha, and many others. Several of the main investors from the earlier round also contributed additional funds to the company, which was further strengthened by Kiran Mazumdar-Shaw.
Previous funding rounds and capital allocation
The official communication of the company states that the fresh infusion of funds will be used in more critical areas of operations and within Strategic Programs. One of the key areas to be supported by the funding is the company’s capacity to obtain Good Manufacturing Practices certification for its manufacturing, essential for scaling biotech operations safely.
The fresh capital funds will be used to accelerate the commercialization of its flagship therapy, Qartemi, and significantly boost the company’s internal research and development pipeline. In addition to its domestic operations, investment in the company will also drive its ground-breaking expansion plans in the wider Asia Pacific region and beyond, where it will ensure its presence in new international healthcare markets.
Immuneel Therapeutics raised approximately ₹12 million through an extension to its Series A funding round in the previous week. The post-money valuation of the firm in that extension round had stood at approximately ₹587 crore (approximately $71 million).
Prior to the news of this Series B funding round, Immuneel Therapeutics was able to raise over $40 million in capital. Some of the historical capital raised by the firm includes an impressive $15 million Series A round in 2022, with participation from Eight Roads Ventures, True North, and F-Prime Capital.
Foundational vision and core objective
Immuneel Therapeutics was founded in the year 2018. It was founded with the combined effort of Kiran Mazumdar Shaw, Siddhartha Mukherjee, and Kush Parwar. The specialized startup was built to focus on the highest level of cell and gene therapy development for cancer treatment, including from its early foundations.
The company recently made a momentous achievement by introducing its innovative treatment, ‘Qartemi’, which it formally dubs as the first approved Chimeric Antigen Receptor T-cell therapy in India, for Non-Hodgkin Lymphoma and leukemia. This breakthrough represents a major reversal in both the way advanced local oncologic therapy is offered and the transition from a research institution to an active commercial company.
To ensure the successful launch of its products, Immuneel Therapeutics is actively increasing its geographic and clinical reach through partnerships with important international collaborators. In particular, Immuneel Therapeutics has been able to develop clinical co-development partnerships in Australia and Southeast Asia.
The core objective of these global strategic partnerships is to increase access to patients to advanced and life-saving cancer treatments in competitive international markets. The company is leveraging local manufacturing capabilities and global clinical networks to offer its product portfolio to comply with international standards while increasing its market presence beyond the Indian subcontinent.
Conclusion
With the success of its Series B round of funding worth more than ₹100 crore, Immuneel Therapeutics has made a strong presence in the Indian biotechnology and oncology arena. The company’s founders’ visionary leadership and the support of a powerful group of institutional and individual investors have helped prepare the way for the scaling of the company’s manufacturing and the rapid acceleration of its commercial objectives.
The startup’s groundbreaking approach in this intricate field of cell and gene therapy could transform the landscape of advanced cancer care and enhance its accessibility both regionally and worldwide.
Read the full article here